

TSINGOS CHRISTINE A
Form 4
December 14, 2017

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
TSINGOS CHRISTINE A

2. Issuer Name and Ticker or Trading Symbol
BIO RAD LABORATORIES INC
[BIO, BIOB]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction
(Month/Day/Year)
12/14/2017

____ Director
 Officer (give title below)
____ 10% Owner
____ Other (specify below)
EVP and CFO

C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
____ Form filed by More than One Reporting Person

HERCULES, CA 94547

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) | | |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|------------|---|
| | | | Code | V | Amount | (D) | Price | | |
| Bio-Rad A Common Stock | 12/14/2017 | | M | | 600 | A | \$ 98.04 | 7,283.0979 | D |
| Bio-Rad A Common Stock | 12/14/2017 | | M | | 1,300 | A | \$ 107.32 | 8,583.0979 | D |
| Bio-Rad A | 12/14/2017 | | M | | 1,280 | A | \$ 117 | 9,863.0979 | D |

Edgar Filing: TSINGOS CHRISTINE A - Form 4

| | | | | | | | | |
|------------------------|------------|--|---|-------|---|------------------------------|-------------|---|
| Common Stock | | | | | | | | |
| Bio-Rad A Common Stock | 12/14/2017 | | M | 800 | A | \$ 119.54 | 10,663.0979 | D |
| Bio-Rad A Common Stock | 12/14/2017 | | M | 1,000 | A | \$ 139.56 | 11,663.0979 | D |
| Bio-Rad A Common Stock | 12/14/2017 | | S | 4,980 | D | \$ 249.4016 <u>(1)</u> | 6,683.0979 | D |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Security (Instr. 3 and 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|
| | | | | | | Date Exercisable Expiration Date | Title |
| | | | | Code | V (A) (D) | | Amount or Number of Shares |
| Non-Qualified Stock Option (right to buy) | \$ 98.04 | 12/14/2017 | | M | 600 | <u>(2)</u> 11/04/2021 | Bio-Rad A Common Stock 600 |
| Non-Qualified Stock Option (right to buy) | \$ 107.32 | 12/14/2017 | | M | 1,300 | <u>(3)</u> 09/12/2022 | Bio-Rad A Common Stock 1,300 |
| Non-Qualified Stock Option (right to buy) | \$ 117 | 12/14/2017 | | M | 1,280 | <u>(4)</u> 09/11/2023 | Bio-Rad A Common 1,280 |

| Option Type | Exercise Price | Grant Date | Relationship | Quantity | Expiration | Stock Type | Quantity |
|---|----------------|------------|--------------|----------|----------------|------------------------|----------|
| Non-Qualified Stock Option (right to buy) | \$ 119.54 | 12/14/2017 | M | 800 | (5) 09/10/2024 | Bio-Rad A Common Stock | 800 |
| Non-Qualified Stock Option (right to buy) | \$ 139.56 | 12/14/2017 | M | 1,000 | (6) 09/11/2025 | Bio-Rad A Common Stock | 1,000 |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|--|---------------|-----------|-------------|-------|
| | Director | 10% Owner | Officer | Other |
| TSINGOS CHRISTINE A C/O BIO-RAD LABORATORIES, INC. 1000 ALFRED NOBEL DRIVE HERCULES, CA 94547 | | | EVP and CFO | |

Signatures

Christine A. Tsingos 12/14/2017

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$249.15 to \$249.54, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- (1) The option vested in five equal annual installments beginning November 4, 2012.
- (3) The option vested in five equal annual installments beginning September 12, 2013.
- (4) The option vested in five equal annual installments beginning September 11, 2014.
- (5) The option vested in five equal annual installments beginning September 10, 2015.
- (6) The option vested in five equal annual installments beginning September 11, 2016.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.